Today: 28 June 2026
Browse Category

NASDAQ:BSX 30 December 2025 - 10 February 2026

Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus

Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus

Boston Scientific shares rose 0.7% to $74.61 by early afternoon Tuesday after a 2.8% drop Monday. New four-year Farapulse data showed higher treatment success than thermal ablation, with no long-term safety issues. Around 9.1 million shares traded by 1:15 p.m. The next major update is expected from the CHAMPION-AF trial results at ACC.26 on March 28.
10 February 2026
··
Boston Scientific stock price steadies after historic plunge as investors zero in on heart-rhythm outlook

Boston Scientific stock price steadies after historic plunge as investors zero in on heart-rhythm outlook

Boston Scientific shares slipped 0.2% to $77.49 in late-morning trading Friday, lagging a broader market rally. The stock remains under pressure after its electrophysiology segment missed sales estimates in the fourth quarter, triggering its steepest drop in over 25 years. Investors are watching for signs management can meet first-quarter growth targets. Trading volume stayed elevated as analysts revised forecasts.
6 February 2026
·
Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific shares rose 1.7% to $93.87 Friday afternoon, outpacing a broader market decline. The move comes ahead of the company’s Feb. 4 earnings report and conference call, its first since announcing a $14.5 billion deal to acquire Penumbra. Investors are watching for details on the acquisition’s impact and the 2026 outlook.
30 January 2026
···
Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings

Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings

Boston Scientific shares rose 1.7% to $94.12 Monday, outpacing medical-device peers and the S&P 500. Evercore reaffirmed its Outperform rating and $112 target, dismissing concerns about the $14.5 billion Penumbra acquisition. Investors await the Feb. 4 earnings call for updates on integration, financing, and demand trends. The Penumbra deal is expected to close in 2026.
26 January 2026
··

Stock Market Today

  • GM Stock Doubles in 3 Years: 3 Reasons for Continued Growth
    June 28, 2026, 5:18 PM EDT. General Motors (GM) stock has surged 116% over three years, outperforming the S&P 500. Key drivers include GM's substantial share buybacks reducing outstanding shares by 500 million, boosting shareholder value. GM's OnStar and Super Cruise software subscriptions deliver high-margin, recurring revenue of over $2.7 billion realized and $5.4 billion deferred. The company anticipates further growth this year, with expected revenues of $3.1 billion realized and $7.5 billion deferred from these services. GM aims to achieve profitability in electric vehicles within three to five years, supported by strong cash flow from truck and SUV sales. Investors who overlooked GM's rise may find value in its robust buyback strategy, expanding software businesses, and EV prospects, positioning the stock for continued gains.

Latest articles

Bradesco (BBDC4) lags as Brazil bank stocks rise; heavy volume on slow days

Bradesco (BBDC4) lags as Brazil bank stocks rise; heavy volume on slow days

28 June 2026
Bradesco preferred shares rose 2.6% last week but lagged the Ibovespa’s 3.0% gain, with over half of BBDC4’s weekly turnover concentrated in two sessions where the stock slipped; investors now eye the July 3 dividend record date and July 6 ex-date, with the declared dividend equaling about 1.6% of BBDC4’s Friday close.
Nu Holdings shares finish up for the week after Needham call

Nu Holdings shares finish up for the week after Needham call

28 June 2026
Nu Holdings (NYSE:NU) surged 5.7% to $13.17 Friday, flipping its week to a 3.6% gain and outperforming both the iShares MSCI Brazil ETF and the Nasdaq, after Needham initiated coverage with a $17 price target, citing a “scaled and profitable customer base” and expected U.S. expansion within a year.
Go toTop